Adenuric febuxostat regulatory update

EMA’s CHMP recommended approval of an expanded label for Adenuric febuxostat from Menarini to include prevention and treatment of hyperuricemia in adults undergoing chemotherapy for hematologic malignancies at intermediate to high risk of tumor lysis syndrome. The non-purine selective inhibitor of xanthine oxidase is marketed in the EU to treat chronic hyperuricemia in conditions where urate deposition has already occurred, including a history or presence of tophus and/or gouty arthritis. ...